BMO Capital analyst Jim Birchenough weighed in with a few insights on bluebird bio Inc (NASDAQ:BLUE) after the company announced that the NIH’s Recombinant DNA …
CTI BioPharma Corp (NASDAQ:CTIC) shares increased 9.6% to $2.
Maxim Group analyst Jason McCarthy weighed in today with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the company made amendments on its …
In research report issued today, J.P.
bluebird bio Inc (NASDAQ:BLUE), a clinical-stage company committed to developing potentially transformative gene therapies for severe genetic and rare diseases and T cell-based …
In a research report issued today, Maxim Group analyst Jason Mccarthy maintained a Buy rating on bluebird bio Inc (NASDAQ:BLUE) with a price …
In a research report issued today, Piper Jaffray analyst Joshua Schimmer maintained an Overweight rating on bluebird bio Inc (NASDAQ:BLUE), and raised the …
Piper Jaffray analyst Joshua Schimmer weighed in today with a few insights on bluebird bio Inc (NASDAQ:BLUE), after the company announced that data from its ongoing Phase …
bluebird bio Inc (NASDAQ:BLUE) keeps hitting its marks. The first Sickle Cell patient treated with LengiGlobin, bluebird’s one-time gene therapy product, is producing healthy red …
bluebird bio Inc (NASDAQ:BLUE) ares increased 3.8% to $179 in pre-market trading after the company announced it will be presenting data on LentiGlobin, a …
